Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL) PR Newswire NEW BRUNSWICK, N.J., May 2, 2013 NEW BRUNSWICK, N.J., May 2, 2013 /PRNewswire/ --Janssen R&D Ireland (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Friday, May 3, at approximately 8:30 a.m., Eastern Time, to discuss simeprevir phase 3 clinical data presented at The International Liver Congress of the European Associationfor the Study of the Liver (EASL). A pre-recorded webcast featuring management from Janssen will provide an overview of results from the phase 3 QUEST -1 and QUEST-2 studies of the investigational protease inhibitor simeprevir (TMC435) administered once daily in combination with pegylated interferon and ribavirin in treatment-naive genotype 1 chronic hepatitis C patients. The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations." SOURCE Johnson & Johnson Website: http://www.jnj.com Contact: Press: Al Wasilewski, (732) 524-1130, Ernie Knewitz, (732) 524-6623, Investor: Lesley Fishman, (732) 524-3922, Lisa Romanko, (732) 524-2034
Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International
Press spacebar to pause and continue. Press esc to stop.